Core Viewpoint - The company has voluntarily applied for the dissolution of its non-wholly owned subsidiary, Shanghai Maiji Biotechnology Co., Ltd., to focus on its core business and streamline operations [1] Company Summary - Shanghai Maiji was established on June 26, 2017, in China and engaged in the research and development of GLP-2, a peptide hormone involved in gut function and metabolism [1] - The decision for dissolution was made based on a shareholder resolution dated October 11, 2025, and is in accordance with Chinese law [1] - The board believes that the dissolution will not adversely affect the overall business operations and financial condition of the company or the group [1] Management Information - Michael Min Xu, the company's chairman, executive director, and general manager, is also an executive director of Shanghai Maiji, and the announcement serves to provide updated information about him as per the Hong Kong Stock Exchange Listing Rules [1]